Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Can the patient sustain the result
The frequency of use will depend on the advice of your healthcare provider
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Keep reading to learn more, navigate to the FAQ below and visit the Quarterly Drug Pipeline for more clinical insights on anticipated drugs in development
US$ 24.56
US$ 27.19
US$ 29.82
US$ 21.32
US$ 25.64
US$ 24.74
US$ 25.12
US$ 26.75
